{"article": [{"url": "https://www.marketwatch.com/story/modernas-stock-rallies-11-as-it-begins-phase-3-trial-for-covid-19-vaccine-2020-07-27", "published": 1595834840.0, "headline": "Moderna's stock rallies 11% as it begins Phase 3 trial for COVID-19 vaccine", "body": "Shares of Moderna Inc. MRNA, +0.09% gained 11.3% in premarket trading on Monday after the company said it started to dose participants in the Phase 3 trial for its experimental COVID-19 vaccine. Moderna also announced Sunday that it will receive additional funding of up to $472 million of its vaccine candidate from the Biomedical Advanced Research and Development Authority to help fund the addition of more participants in the late-stage trial. (Moderna previously announced it had been awarded $483 million in federal funding to support clinical development of the vaccine.) The Phase 3 randomized, placebo-controlled trial, which is being conducted with the National Institute of Allergy and Infectious Diseases, is expected to enroll up to 30,000 people, who will receive a 100 microgram dose of the investigational vaccine. The primary endpoint is preventing symptomatic COVID-19 disease, and the secondary endpoints are preventing severe forms of COVID-19 that require hospitalization and preventing contracting the virus altogether. Moderna's stock has soared 274.2% since the start of the year, while the S&P 500 SPX, +0.87% is down 0.4%."}]}